No­vo Nordisk takes $816M write­down af­ter Phase 3 fail in chron­ic kid­ney dis­ease

No­vo Nordisk said Wednes­day morn­ing a small mol­e­cule that it re­cent­ly bought for up to $1.3 bil­lion has failed a Phase 3 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland